All News

The final rule requires Part D plans to adopt tools that provide clinicians with information that they can discuss with patients on out-of-pocket costs for prescription drugs at the time a prescription is written.

Dalteparin sodium is the first anticoagulant indicated for pediatric patients approved by the agency.

VTE can include deep vein thrombosis and pulmonary embolism, which can lead to death.

When both of these compounds are in abundant supply, good things happen.

An analysis showed short-term health plans can expose enrollees to significant out-of-pocket costs for serious illnesses, such as cancer.

Study explored a novel drug’s efficacy in overcoming ibrutinib-resistant mantle cell lymphoma.

Top news of the day from across the health care landscape.

The annual KANTAR Readership Study encompasses readership habits of thousands of pharmacists and pharmacy professionals, working in the areas of chain, independent retail pharmacies and health-system pharmacies.

Civica has made plans to deliver 14 essential generic medications this year.

The approval of venetoclax (Venclexta) in combination with obinutuzumab (Gazyva) offers an additional option for adults with previously-untreated chronic lymphocytic leukemia.

This report revealed that in 2016, an estimated 3900 of 4200 or 93% incident HIV infections among black women would not have occurred if the incidence for black women were the same as that for white women.

This first-to-market point-of-sale platform combines industry expertise, artificial intelligence and comprehensive, deep-data libraries to seek out and identify errors so that the right discounts are applied to the right transaction.

The FDA’s Oncology Drugs Advisory Committee challenged the results of the phase 3 QuANTUM-R study.

Avelumab (Bavencio) plus axitinib (Inlyta) is indicated for the first-line treatment of patients with advanced renal cell carcinoma.

Top news of the day from across the health care landscape.

Risdiplam showed continued improvements in motor milestones and functions for patients with spinal muscular atrophy.

This is the first FDA approval for an anti-PD-L1 therapy as part of a combination regimen for patients with advanced RCC, according to EMD Serono.

The lawsuit, filed in U.S. District Court for the District of Connecticut, alleges a broad conspiracy to artificially inflate and manipulate prices, reduce competition, and unreasonably restrain trade for more than 100 different generic drugs.

Amber Draper, PharmD, BCOP, clinical pharmacist, Winship Cancer Institute in Georgia discusses current recommendations for colon cancer screening. This video was filmed at the 2019 Hematology/Oncology Pharmacy Association Annual Conference in Fort Worth, Texas.

In addition to first-line treatment of blepharospasm, the drug is indicated for adult patients with cervical dystonia, upper limb spasticity, and chronic sialorrhea, or excessive drooling.

In 2016, an estimated 93% incident HIV infections among black women would not have occurred if the incidence for black women were the same as that for white women, according a CDC report.

On August 30, 2018, the FDA approved Merck’s doravirine (Pifeltro) a non-nucleoside reverse transcriptase inhibitor and doravirine/lamivudine/tenofovir (Delstrigo) a once-daily single tablet regimen for the treatment of HIV-1 infection in appropriate patients.

Procedure uses small incisions and a miniature video camera to reduce the risk of complications from surgery for lung cancer.

Top news of the day from across the health care landscape.

The FDA's approval was based on 6-month and 1-year results from the PANORAMA clinical trial.

Kaposi sarcoma is a cancer caused by an associated herpesvirus that develops from the cells that line lymph or blood vessels, and most commonly affects individuals with HIV.

The novel intravenous immune globulin (IVIG) product is indicated for individuals with primary humoral immunodeficiency disease (PIDD), which includes X-linked and congenital agammaglobulinemia, common variable immunodeficiency, Wiskott-Aldrich syndrome, and severe combined immunodeficiency.

The FDA approved a Prior Approval Supplement for immune globulin intravenous (human), 10% liquid (Bivigam, ADMA Biologics) for patients with primary humoral immunodeficiency disease.